Eikon Therapeutics (EIKN) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Underperform | $4.00 from $5.00 | Aug 14, 2026 |
| Wedbush | Maintained | Underperform | $5.00 from $7.00 | May 12, 2026 |
| Wedbush | Maintained | Underperform | $7.00 | Mar 31, 2026 |
| B of A Securities | Initiated Coverage | Buy | $34.00 | Mar 2, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $29.00 | Mar 2, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $32.00 | Mar 2, 2026 |
| Mizuho | Initiated Coverage | Outperform | $26.00 | Mar 2, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 2, 2026 |
| Wedbush | Initiated Coverage | Underperform | $7.00 | Feb 26, 2026 |
Frequently asked questions
Is EIKN a buy, sell, or hold?
Analysts covering Eikon Therapeutics currently average a Buy rating: 5 buy, 0 hold and 1 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on EIKN?
On Aug 14, 2026, Wedbush maintained Eikon Therapeutics at Underperform with a price target of $4.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.